Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
C J HolubarschJaan Eha

Abstract

Preparations from Crataegus (hawthorn) have a long history in the treatment of heart failure. WS 1442 is a dry extract from hawthorn leaves with flowers (4-6.6:1), extraction solvent of ethanol 45% (w/w), adjusted to 17.3-20.1% of oligomeric procyanidins. Nonclinical studies show that WS 1442 has positive inotropic and antiarrhythmic properties and protects the myocardium from ischemic damage, reperfusion injury, and hypertension-related hypertrophy, improves endothelial functions such as NO synthesis, and delays endothelial senescence. Randomized, controlled trials in patients with heart failure have demonstrated that the herbal medicinal product increases functional capacity, alleviates disabling symptoms, and improves health-related quality of life, all of which have become important targets of heart failure therapy according to current disease management guidelines. Clinical trials (including a 2-year mortality study with polypharmacy and > 1300 patients exposed) and post-marketing surveillance studies have shown that WS 1442 has a very favorable safety profile both as monotherapy and as add-on therapy, where no drug interactions have been observed. No specific adverse reactions to WS 1442 are known to date. WS 1442 may thu...Continue Reading

References

Sep 1, 1996·The American Journal of Emergency Medicine·R M GoldbergS Wong
Apr 12, 2000·Journal of the American College of Cardiology·C P GreenJ A Spertus
May 17, 2000·Journal of Cardiovascular Pharmacology·R H SchwingerK Brixius
Sep 12, 2000·Current Cardiology Reports·P J Podrid
Oct 31, 2000·Critical Care Medicine·G M Chaudhry, C I Haffajee
Aug 23, 2001·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·G Zapfe jun
Feb 11, 2005·Pharmazie in unserer Zeit·Klara BrixiusRobert H G Schwinger
Aug 10, 2005·European Journal of Heart Failure·Inger EkmanKarl Swedberg
Jun 7, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Claudia DanieleEdzard Ernst
Sep 12, 2006·European Heart Journal·John G F ClelandUNKNOWN PEP-CHF Investigators
Feb 7, 2008·The Cochrane Database of Systematic Reviews·M H PittlerE Ernst
Nov 13, 2008·The New England Journal of Medicine·Barry M MassieUNKNOWN I-PRESERVE Investigators
Nov 21, 2008·European Journal of Heart Failure·Christian J F HolubarschMichal Tendera
Oct 1, 2009·European Journal of Heart Failure·Suzanna M ZickKeith D Aaronson
Nov 10, 2010·Nature Reviews. Cardiology·Anh L BuiGregg C Fonarow
Sep 9, 2011·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Eva RieckeheerKlara Brixius
May 25, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·N Idris-KhodjaV B Schini-Kerth
Oct 1, 2013·Expert Opinion on Drug Safety·Robert L MaherEmily R Hajjar
Oct 29, 2013·BMJ : British Medical Journal·Daniel K Sokol
Jan 25, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Jie WangBo Feng
Apr 11, 2014·The New England Journal of Medicine·Bertram PittUNKNOWN TOPCAT Investigators
May 29, 2014·Therapeutische Umschau. Revue thérapeutique·Beate Wickop, Claudia Langebrake
Jul 17, 2014·Pflügers Archiv : European journal of physiology·Hans Oberleithner
Apr 4, 2015·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·UNKNOWN Deutsche Gesellschaft für Kardiologie- Herz- und Kreislaufforschung
Dec 18, 2015·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Sonia Khemais-BenkhiatValérie B Schini-Kerth
May 4, 2017·European Journal of Heart Failure·Michel KomajdaUNKNOWN prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators

❮ Previous
Next ❯

Citations

Jan 25, 2020·Journal of Hypertension·Claudio BorghiGiuseppe Mancia
May 4, 2018·MMW Fortschritte der Medizin·Gustav J Dobos
Mar 11, 2020·Frontiers in Pharmacology·Min WuYu Cao
Jul 6, 2018·MMW Fortschritte der Medizin·Tankred WegenerRainer Stange
Dec 11, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Phu Cao NgocHervé Cottet
Aug 14, 2019·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Katherine G PalmerRebekah A Burns
Oct 21, 2020·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Anita MudanJacob Lebin

❮ Previous
Next ❯

Software Mentioned

SPICE

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Janene M Rigelsky, Burgunda V Sweet
American Family Physician
Stephen Dahmer, Emilie Scott
Fortschritte der Medizin
T Weihmayr, Edzard Ernst
© 2022 Meta ULC. All rights reserved